A new, costly cancer drug vs placebo; Cabozantinib in neuroendocrine tumors; How NIH funded trials can fail patients and payers
Sensible Medicine
FEBRUARY 17, 2025
John is sick, so I have big shoes to fill. Today’s study of the week is a cancer trial. I know many of you aren’t cancer doctors, and you are thinking about skipping this essay. Let me assure you: you will learn something. The trial has issues with control arm, skewed randomization (2:1), drop out and endpoints. It is a rollercoaster ride of critical appraisal.
Let's personalize your content